ATE252896T1 - Endokrintherapie für brustkrebs: kombinierte behandlung mit tamoxifen und alkyl-pcdfs - Google Patents

Endokrintherapie für brustkrebs: kombinierte behandlung mit tamoxifen und alkyl-pcdfs

Info

Publication number
ATE252896T1
ATE252896T1 AT99967497T AT99967497T ATE252896T1 AT E252896 T1 ATE252896 T1 AT E252896T1 AT 99967497 T AT99967497 T AT 99967497T AT 99967497 T AT99967497 T AT 99967497T AT E252896 T1 ATE252896 T1 AT E252896T1
Authority
AT
Austria
Prior art keywords
pcdfs
alkyl
tamoxifen
breast cancer
combined treatment
Prior art date
Application number
AT99967497T
Other languages
English (en)
Inventor
Stephen H Safe
Original Assignee
Texas A & M Univ Sys
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas A & M Univ Sys filed Critical Texas A & M Univ Sys
Application granted granted Critical
Publication of ATE252896T1 publication Critical patent/ATE252896T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99967497T 1998-12-21 1999-12-21 Endokrintherapie für brustkrebs: kombinierte behandlung mit tamoxifen und alkyl-pcdfs ATE252896T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/217,780 US6136845A (en) 1998-12-21 1998-12-21 Endocrine therapy for breast cancer: combined treatment with tamoxifen plus alkyl PCDFs
PCT/US1999/030554 WO2000037065A2 (en) 1998-12-21 1999-12-21 Endocrine therapy for breast cancer: combined treatment with tamoxifen plus alkyl pcdfs

Publications (1)

Publication Number Publication Date
ATE252896T1 true ATE252896T1 (de) 2003-11-15

Family

ID=22812479

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99967497T ATE252896T1 (de) 1998-12-21 1999-12-21 Endokrintherapie für brustkrebs: kombinierte behandlung mit tamoxifen und alkyl-pcdfs

Country Status (9)

Country Link
US (1) US6136845A (de)
EP (1) EP1140047B1 (de)
JP (1) JP2002532546A (de)
AT (1) ATE252896T1 (de)
AU (1) AU772920B2 (de)
CA (1) CA2356624A1 (de)
DE (1) DE69912477T2 (de)
ES (1) ES2207981T3 (de)
WO (1) WO2000037065A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709520B2 (en) 2000-10-06 2010-05-04 The Texas A&M University System Diindolylmethane and C-substituted diindolylmethane compositions and methods for the treatment of multiple cancers
CN100545158C (zh) * 2003-10-14 2009-09-30 科学和工业研究理事会 具有雌激素活性的(3r,4r)-反-3,4-二芳基苯并二氢吡喃衍生物
CN1318411C (zh) * 2005-03-21 2007-05-30 中国海洋大学 氢化轮枝霉酮类化合物及其制备方法和用途
US9517240B2 (en) 2006-09-26 2016-12-13 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
WO2008039482A2 (en) * 2006-09-26 2008-04-03 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
DK2200994T3 (da) * 2007-10-26 2014-04-22 Acadia Pharm Inc Kondenserede forbindelser med aktivitet ved estrogenreceptorer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656187A (en) * 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
US5516790A (en) * 1989-01-23 1996-05-14 Texas A&M University System Technology Licensing Office Synthesis and application of alkyl-substituted dibenzofurans as antitumorigenic agents
US5604248A (en) * 1994-05-05 1997-02-18 Eli Lilly And Company Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs

Also Published As

Publication number Publication date
EP1140047A2 (de) 2001-10-10
WO2000037065A3 (en) 2000-09-14
CA2356624A1 (en) 2000-06-29
AU2376600A (en) 2000-07-12
AU772920B2 (en) 2004-05-13
ES2207981T3 (es) 2004-06-01
WO2000037065A2 (en) 2000-06-29
DE69912477T2 (de) 2004-08-19
EP1140047B1 (de) 2003-10-29
US6136845A (en) 2000-10-24
DE69912477D1 (de) 2003-12-04
JP2002532546A (ja) 2002-10-02

Similar Documents

Publication Publication Date Title
ATE331534T1 (de) Anwendung von zielgerichtetem radium 223 für palliative und therapeutische behandlung von knochenkrebs
AU5338301A (en) Methods and compositions for modulating alpha adrenergic receptor activity
PT1472541E (pt) Agentes de imagiologia e métodos de imagiologia de naaladase de psma
DE60112974D1 (en) Carbolinderivate
BR0309875A (pt) métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto
UA70925C2 (uk) Спосіб лікування естрогенстимульованого раку
MXPA04003674A (es) Uso mejorado de compuesto antitumoral en terapia de cancer.
TR200100054T2 (tr) Paroksetin metansülfonat
DK1104425T3 (da) Hidtil ukendte thiazolopyrimidinforbindelser
WO2003087831A3 (en) Proteins involved in breast cancer
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
AR052774A1 (es) Inmunoterapia para trastornos autoinmunes
BR0010702A (pt) Novas quinonas como terapias de doenças
SE9802208D0 (sv) Novel compounds
SE9903997D0 (sv) New compounds
ATE252896T1 (de) Endokrintherapie für brustkrebs: kombinierte behandlung mit tamoxifen und alkyl-pcdfs
BR0109789A (pt) Método para o tratamento de câncer de mama, e, uso de fulvestrante
MXPA03011270A (es) Uso de antagonistas rank para tratar cancer.
TR200101693T2 (tr) Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
SE9802209D0 (sv) Novel compounds
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
PT1206256E (pt) Terapia de combinacao utilizando pentafluorobenzenosulfonamida e compostos de platina
ATE386029T1 (de) Urokinase-inhibitoren
ATE329597T1 (de) Die verwendung von einer 4- pyridylmethylphtalazine enthaltenden kombination zur behandlung von tumoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties